Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending December 2012. The report details a specific share repurchase transaction executed on December 3, 2012, in accordance with shareholder authority granted at the Annual General Meeting on May 3, 2012.
Key Financial Metrics
The filing does not provide comprehensive financial statements such as revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on capital structure changes related to share buybacks.
- Shares Purchased: 724,775 Ordinary Shares of 25 pence each.
- Purchase Price Range: Highest price paid was 1,344.5 pence per share; lowest price paid was 1,333.5 pence per share.
- Treasury Shares Held: 490,140,427 shares (representing 9.08% of total issued share capital).
- Voting Rights Impact: Including unsettled purchases, treasury shares represent 9.98% of total voting rights.
- Shares in Issue: 4,909,837,749 shares (excluding treasury shares).
Material Changes
The primary material change reported is the reduction of outstanding share capital through the cancellation of 724,775 shares purchased on December 3, 2012. The filing does not provide comparative data against prior periods for financial performance.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, or discussion of risks and contingencies. It is a regulatory disclosure confirming compliance with the Financial Services Authority's Disclosure and Transparency Rules regarding share buybacks.
Investor Verification Checklist
- Verify the total number of shares held in treasury (490,140,427) against the company's latest annual report.
- Confirm the calculation of voting rights (9.98%) including unsettled transactions.
- Check the total issued share capital excluding treasury shares (4,909,837,749) for accurate EPS and ownership percentage calculations.
- Note that this filing does not contain operational or financial performance data; refer to Form 20-F for full financial results.